Sinil Pharmaceutical Balance Sheet Health
Financial Health criteria checks 6/6
Sinil Pharmaceutical has a total shareholder equity of ₩134.9B and total debt of ₩0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ₩152.5B and ₩17.6B respectively. Sinil Pharmaceutical's EBIT is ₩14.0B making its interest coverage ratio -17. It has cash and short-term investments of ₩23.4B.
Key information
0%
Debt to equity ratio
₩0
Debt
| Interest coverage ratio | -17x |
| Cash | ₩23.42b |
| Equity | ₩134.90b |
| Total liabilities | ₩17.56b |
| Total assets | ₩152.46b |
Recent financial health updates
No updates
Recent updates
Are Sinil Pharmaceutical Co., Ltd.'s (KOSDAQ:012790) Mixed Financials Driving The Negative Sentiment?
Mar 11
Is Sinil Pharmaceutical's (KOSDAQ:012790) 122% Share Price Increase Well Justified?
Feb 13
Could The Sinil Pharmaceutical Co., Ltd. (KOSDAQ:012790) Ownership Structure Tell Us Something Useful?
Jan 17Sinil Pharmaceutical's (KOSDAQ:012790) Earnings Are Growing But Is There More To The Story?
Dec 22Are Sinil Pharmaceutical Co., Ltd.'s (KOSDAQ:012790) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?
Nov 26Financial Position Analysis
Short Term Liabilities: A012790's short term assets (₩68.8B) exceed its short term liabilities (₩14.1B).
Long Term Liabilities: A012790's short term assets (₩68.8B) exceed its long term liabilities (₩3.4B).
Debt to Equity History and Analysis
Debt Level: A012790 is debt free.
Reducing Debt: A012790 had no debt 5 years ago.
Debt Coverage: A012790 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: A012790 has no debt, therefore coverage of interest payments is not a concern.